Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California–(Newsfile Corp. – August 19, 2026) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora”) today announced that…